Interleukin-4 and -13 Receptors: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Biochemistry & Molecular Biology
Contributor:
Xujun Song

Interleukin (IL)-4 and -13 are structurally and functionally related cytokines sharing common receptor subunits. They regulate immune responses and, moreover, are involved in the pathogenesis of a variety of human neoplasms. In this entry, their possible roles in gastric cancer were shown as an example.

  • interleukin-4
  • interleukin-13
  • interleukin-4 receptor
  • interleukin-13 receptor

1. Introduction

Gastric cancer (GC) and colon and rectal cancer (CRC) are common malignancies of the digestive system [1][2]. Despite advances in earlier detection, multimodal treatment, and surgical management, the prognosis of both entities is still unsatisfactory [3]. CRC is the second leading cause of all tumor deaths in the United States [3], and stomach cancer is the third leading death cause of cancer-related deaths worldwide [4]. Alternative or additional treatment strategies especially for advanced tumor stages are desperately needed to overcome drug resistance, enhance chemosensitivity, inhibit tumor cell proliferation, and induce apoptosis in order to further improve outcome [1][2][5][6][7][8][9].

More and more evidence has been provided in recent years that interleukin-4 (IL-4), interleukin-13 (IL-13), and their receptors play an important role in cancer cell proliferation and other biological behaviors, such as migration and invasion enhancing the malignant phenotype [10][11][12]. Moreover, IL-4/IL-13 and their receptors have been also associated with apoptosis, chemosensitivity, and prognosis in various cancers [13][14][15]. IL-4 and IL-13 are also involved in the crosstalk with the tumor microenvironment (TME) by activating tumor-associated macrophages and myeloid-derived suppressor cells, which have tumor promoting functions [16][17]. Immune surveillance against established metastatic mammary cancer is negatively regulated by IL-13 in mice [18].

2. Summary of the IL-4/-13 Signaling Pathway

IL-4, first described in 1981, is a secreted cytokine that, in its physiologic function, can regulate antibody production, hematopoiesis, and inflammation, and is also involved in the development of effector T-cell responses [19]. The closely related IL-13, first described in 1993, is a human lymphokine that can regulate inflammatory and immune responses [20]. IL-4 and IL-13 are essential for the induction and persistence of the type 2 immune response, and they are associated with multiple atopic diseases, such as asthma and atopic dermatitis [21]. IL-4 and IL-13 are mainly produced by immune cells, such as CD4-T-cells, basophils, eosinophils, and natural killer T (NKT) cells [22].

The structure of IL-4 receptor (IL-4R), IL-13 receptor (IL-13R), and the positions of the intracellular signaling molecules of them have been summarized in several articles [23][24][25][26]. There are three different kinds of IL-4 receptors (Figure 1). IL-4 binds to the IL-4Rα chain, then recruits the IL-2Rγ-common (γc) chain (type I IL-4R) or the IL-13Rα1 chain (type II IL-4R) to form a receptor complex that can initiate signal transduction [25]. The type III IL-4R is formed by all the three chains [27]. IL-13 can also signal via three different receptors (Figure 1). The type II IL-13R complex has the same components as the type II IL-4R [28]. IL-13R type I (IL-4Rα/IL-13Rα1/IL-13Rα2) and type II (IL-4Rα/IL-13Rα1) are expressed in non-hematopoietic cells, while type III (IL-4Rα/IL-13Rα1/γc) is only expressed on the surface of hemocytes [27]. Overall, this results in a possible complex web of IL-4– and IL-13–mediated signaling pathways [29].

Ijms 22 00727 g001 550

Figure 1. Receptor types and signal transduction of IL-4R and IL-13R. There are three different kinds of IL-4 receptors. IL-4 binds to the IL-4Rα chain, then recruits the IL-2Rγ-common (γc) chain (type I IL-4R) or the IL-13Rα1 chain (type II IL-4R) to form a receptor complex that can initiate signal transduction. The type III IL-4R consists of all three chains. IL-13 also have three different receptors. IL-13 receptor type I (IL-4Rα/IL-13Rα1/IL-13Rα2) and type II (IL-4Rα/IL-13Rα1) are expressed in solid tumors, while type III (IL-4Rα/IL-13Rα1/γc) is expressed in hemocytes only. IL-13 binds IL-13Rα1 with a low affinity and complexes with the IL-4Rα (type II receptor). IL-13 binds to the IL-13Rα2 with a high affinity. IL-13 can bind to a soluble IL-13Rα2 receptor, which has no downstream signaling, or bind to transmembrane IL-13Rα2 and activate AP-1. Figure sketch adapted from reference [27].

With regard to the IL-13Rα2 chain, IL-13 is not the sole ligand. For example, chitinase-3-like protein 1 (CHI3L1) could bind to IL-13Rα2 and regulate oxidant injury, apoptosis, and melanoma metastasis [30]. Transmembrane protein 219 and CD44 play an important role in IL-13Rα2 mediated signaling which is induced by CHI3L1 [31][32].

Altogether, IL-4R and IL-13R share two receptor chains (IL-4Rα and IL-13Rα1) and can mediate common, but also diverse biological functions [27]. Both IL-4 and IL-13 phosphorylate and activate signal transducer and activator of transcription (STAT) 6 [27]. STAT3, STAT5, and STAT1 can also be activated, but to a lesser degree [23]. IL-4 can signal through IRS-2 (generally expressed by hematopoietic cells) or IRS-1 (generally non-hematopoietically expressed) [23]. As mentioned above, IL-13 could bind to the IL-13Rα2 chain, which has a very high affinity for IL-13. The downstream signaling involves AP-1 family members c-jun and Fra-2 [33]. IL-13Rα2 can inhibit downstream signals of IL-13R and IL-4R through regulating STAT6 [34][35].

3. IL-13/IL-13R in Gastric Cancer

IL-13Rs are overexpressed in several human solid cancer cell lines [36][37]. Our group demonstrated that IL-13R and IL-4R were expressed in pancreatic cancer cell lines, such as PANC-1, MIAPaCa-2, and CAPAN-1 [38]. Their proliferation was inhibited by Pseudomonas exotoxin (PE) combined to IL-13 or IL-4, demonstrating the receptor’s functionality [38]. IL-13Rα2 is expressed in HS766T and MIAPaCa-2 pancreatic cancer cells, as well [36]. One recombinant chimeric protein IL-13PE was found highly cytotoxic to GC cell line CRL1739, which also expressed the type II IL-4R receptor (Figure 1) binding both IL-4 and IL-13 [39]. IL-13Rα2 is also expressed in GC cell lines MKN-45, AGS and MGC308 [32][40].

Gabitass et al. evaluated plasma IL-13 and IL-4 levels in 131 patients (46 pancreatic cancer, 25 GC, and 60 esophageal cancer) and 54 healthy controls [41]. IL-13 levels in patients’ plasma were significantly higher in all the three cancer patients compared with controls [41]. In another study, Lin et al. evaluated IL-13Rα2 expression in tissue microarrays of 507 GC patients [15]. They found the overexpression of the IL-13Rα2 chain in cancer tissue was associated with poor prognosis after gastrectomy [15].

Chen and coworkers showed that CHI3L1 secreted by M2 macrophage could promote the metastasis of GC cell lines MKN-45 and AGS by binding to the IL-13Rα2 chain [40]. The mechanism is mediated by activating the mitogen-activated protein kinase signaling pathway, which upregulates the matrix metalloproteinase genes [40]. Geng et al. found CD44v3 could bind to both CHI3L1 and IL-13Rα2 in GC cell lines AGS and MGC308 [32]. In this study, CHI3L1 expression was positively related to GC invasion depth and lymph node status in 100 GC tissues from patients [32].

4. IL-4/IL-4R in Gastric Cancer

Human GC cell lines such as CRL1739 express IL-4R [42]. IL-4 inhibited proliferation of HTB-135 GC cells by down-regulating G0-G1 cell cycle nuclear-regulating factors, including retinoblastoma gene product, c-myc, and cyclin D1 [43]. IL-4 could cause G1 phase arrest in the GC cell line CRL 1739 by binding to IL-4Rα and γc (type I IL-4R) [42]. IL-4 could also inhibit the growth of GC cells and this effect was positively related with IL-4R expression level of the respective cell lines [44]. The expression was detected by flow cytometry using biotin-labeled IL-4. It remains unclear, however, what type of IL-4R causing inhibition of GC cell growth was expressed (Figure 1).

Gabitass et al. found plasma IL-4 levels in 25 GC patients were significantly higher than in 54 healthy controls [41]. Cárdenas et al. found serum IL-4 levels in 17 GC patients were significantly elevated comparing with 30 healthy individuals by sandwich ELISA [45]. In their study, elevated serum levels of IL-4 indicated a higher risk of mortality, but there is no statistical association [45]. Orea and co-workers studied a total of 30 biopsies of GC by immunohistochemistry [46]. They found a significantly higher expression of IL-4 in stages I and II than in stages III and IV, pointing to a possible growth inhibitory effect of IL-4 in GC [46].

This entry is adapted from the peer-reviewed paper 10.3390/ijms22020727

References

  1. Ilson, D.H. Advances in the treatment of gastric cancer. Curr. Opin. Gastroenterol. 2018, 34, 465–468.
  2. Dekker, E.; Tanis, P.J.; Vleugels, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet 2019, 394, 1467–1480.
  3. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30.
  4. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
  5. Selim, J.H.; Shaheen, S.; Sheu, W.C.; Hsueh, C.T. Targeted and novel therapy in advanced gastric cancer. Exp. Hematol. Oncol. 2019, 8, 25.
  6. Patel, T.H.; Cecchini, M. Targeted Therapies in Advanced Gastric Cancer. Curr. Treat. Options Oncol. 2020, 21, 70.
  7. Tolba, M.F. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors. Int. J. Cancer 2020, 147, 2996–3006.
  8. Vincent, A.; Ouelkdite-Oumouchal, A.; Souidi, M.; Leclerc, J.; Neve, B.; Van Seuningen, I. Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies. World J. Stem Cells 2019, 11, 920–936.
  9. Bess, S.N.; Greening, G.J.; Muldoon, T.J. Efficacy and clinical monitoring strategies for immune checkpoInt. inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. Cytokine Growth Factor Rev. 2019, 49, 1–9.
  10. Traub, B.; Sun, L.; Ma, Y.; Xu, P.; Lemke, J.; Paschke, S.; Henne-Bruns, D.; Knippschild, U.; Kornmann, M. Endogenously Ex-pressed IL-4Ralpha Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Int. J. Mol. Sci. 2017, 18, 716.
  11. Bartolome, R.A.; Garcia-Palmero, I.; Torres, S.; Lopez-Lucendo, M.; Balyasnikova, I.V.; Casal, J.I. IL13 Receptor alpha2 Sig-naling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Res. 2015, 75, 2434–2444.
  12. Liu, H.; Antony, S.; Roy, K.; Juhasz, A.; Wu, Y.; Lu, J.; Meitzler, J.L.; Jiang, G.; Polley, E.; Doroshow, J.H. Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells. Oncotarget 2017, 8, 38113–38135.
  13. Barderas, R.; Bartolome, R.A.; Fernandez-Acenero, M.J.; Torres, S.; Casal, J.I. High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res. 2012, 72, 2780–2790.
  14. Todaro, M.; Alea, M.P.; Di Stefano, A.B.; Cammareri, P.; Vermeulen, L.; Iovino, F.; Tripodo, C.; Russo, A.; Gulotta, G.; Medema, J.P.; et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1, 389–402.
  15. Lin, C.; Liu, H.; Zhang, H.; He, H.; Li, H.; Shen, Z.; Qin, J.; Qin, X.; Xu, J.; Sun, Y. Interleukin-13 receptor alpha2 is associated with poor prognosis in patients with gastric cancer after gastrectomy. Oncotarget 2016, 7, 49281–49288.
  16. Ostrand-Rosenberg, S. Immune surveillance: A balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18, 11–18.
  17. Wang, H.W.; Joyce, J.A. Alternative activation of tumor-associated macrophages by IL-4: Priming for protumoral functions. Cell Cycle 2010, 9, 4824–4835.
  18. Sinha, P.; Clements, V.K.; Ostrand-Rosenberg, S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65, 11743–11751.
  19. Brown, M.A.; Hural, J. Functions of IL-4 and Control of Its Expression. Crit. Rev. Immunol. 2017, 37, 181–212.
  20. Minty, A.; Chalon, P.; Derocq, J.M.; Dumont, X.; Guillemot, J.C.; Kaghad, M.; Labit, C.; Leplatois, P.; Liauzun, P.; Miloux, B.; et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993, 362, 248–250.
  21. Gandhi, N.A.; Pirozzi, G.; Graham, N.M.H. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev. Clin. Im-munol. 2017, 13, 425–437.
  22. Junttila, I.S. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. Front. Immunol. 2018, 9, 888.
  23. Luzina, I.G.; Keegan, A.D.; Heller, N.M.; Rook, G.A.; Shea-Donohue, T.; Atamas, S.P. Regulation of inflammation by interleu-kin-4: A review of “alternatives”. J. Leukoc. Biol. 2012, 92, 753–764.
  24. Oh, C.K.; Geba, G.P.; Molfino, N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur. Respir. Rev. 2010, 19, 46–54.
  25. LaPorte, S.L.; Juo, Z.S.; Vaclavikova, J.; Colf, L.A.; Qi, X.; Heller, N.M.; Keegan, A.D.; Garcia, K.C. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008, 132, 259–272.
  26. Ul-Haq, Z.; Naz, S.; Mesaik, M.A. Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. Cytokine Growth Factor Rev. 2016, 32, 3–15.
  27. Suzuki, A.; Leland, P.; Joshi, B.H.; Puri, R.K. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine 2015, 75, 79–88.
  28. Aman, M.J.; Tayebi, N.; Obiri, N.I.; Puri, R.K.; Modi, W.S.; Leonard, W.J. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J. Biol. Chem. 1996, 271, 29265–29270.
  29. Wills-Karp, M.; Finkelman, F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci. Signal. 2008, 1, pe55.
  30. He, C.H.; Lee, C.G.; Dela Cruz, C.S.; Lee, C.M.; Zhou, Y.; Ahangari, F.; Ma, B.; Herzog, E.L.; Rosenberg, S.A.; Li, Y.; et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep. 2013, 4, 830–841.
  31. Lee, C.M.; He, C.H.; Nour, A.M.; Zhou, Y.; Ma, B.; Park, J.W.; Kim, K.H.; Dela Cruz, C.; Sharma, L.; Nasr, M.L.; et al. IL-13Ralpha2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat. Commun. 2016, 7, 12752.
  32. Geng, B.; Pan, J.; Zhao, T.; Ji, J.; Zhang, C.; Che, Y.; Yang, J.; Shi, H.; Li, J.; Zhou, H.; et al. Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through beta-catenin/Erk/Akt signaling in gastric cancer. J. Exp. Clin. Cancer Res. 2018, 37, 208.
  33. Fichtner-Feigl, S.; Strober, W.; Kawakami, K.; Puri, R.K.; Kitani, A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 2006, 12, 99–106.
  34. Wood, N.; Whitters, M.J.; Jacobson, B.A.; Witek, J.; Sypek, J.P.; Kasaian, M.; Eppihimer, M.J.; Unger, M.; Tanaka, T.; Goldman, S.J.; et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J. Exp. Med. 2003, 197, 703–709.
  35. Rahaman, S.O.; Sharma, P.; Harbor, P.C.; Aman, M.J.; Vogelbaum, M.A.; Haque, S.J. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 2002, 62, 1103–1109.
  36. Fujisawa, T.; Joshi, B.; Nakajima, A.; Puri, R.K. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009, 69, 8678–8685.
  37. Murata, T.; Obiri, N.I.; Debinski, W.; Puri, R.K. Structure of IL-13 receptor: Analysis of subunit composition in cancer and immune cells. BioChem. Biophys Res. Commun. 1997, 238, 90–94.
  38. Kornmann, M.; Kleeff, J.; Debinski, W.; Korc, M. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res. 1999, 19, 125–131.
  39. Debinski, W.; Obiri, N.I.; Pastan, I.; Puri, R.K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 1995, 270, 16775–16780.
  40. Chen, Y.; Zhang, S.; Wang, Q.; Zhang, X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J. Hematol. Oncol. 2017, 10, 36.
  41. Gabitass, R.F.; Annels, N.E.; Stocken, D.D.; Pandha, H.A.; Middleton, G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60, 1419–1430.
  42. Essner, R.; Huynh, Y.; Nguyen, T.; Rose, M.; Kojima, M.; Hoon, D.S. Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: A possible mechanism for cytokine-based therapy. J. Gastrointest. Surg. 2001, 5, 81–90.
  43. Morisaki, T.; Uchiyama, A.; Yuzuki, D.; Essner, R.; Morton, D.L.; Hoon, D.S. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. Cancer Res. 1994, 54, 1113–1118.
  44. Morisaki, T.; Yuzuki, D.H.; Lin, R.T.; Foshag, L.J.; Morton, D.L.; Hoon, D.S. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res. 1992, 52, 6059–6065.
  45. Cardenas, D.M.; Sanchez, A.C.; Rosas, D.A.; Rivero, E.; Paparoni, M.D.; Cruz, M.A.; Suarez, Y.P.; Galvis, N.F. Preliminary analysis of single-nucleotide polymorphisms in IL-10, IL-4, and IL-4Ralpha genes and profile of circulating cytokines in patients with gastric Cancer. BMC Gastroenterol. 2018, 18, 184.
  46. Diaz Orea, M.A.; Munoz Perez, V.; Gomez Conde, E.; Castellanos Sanchez, V.O.; Gonzalez Lopez, R.; Flores Alonso, J.C.; Cardenas, M.E.; Galicia, A.L.; Mendoza, A. Expression of Cytokines Interleukin-2, Interleukin-4, Interleukin-10 and Trans-forming Growth Factor beta in Gastric Adenocarcinoma Biopsies Obtained from Mexican Patients. Asian Pac. J. Cancer Prev. 2017, 18, 577–582.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback